{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:43:41Z","timestamp":1795085021666,"version":"4.10.2"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate vascular maturation of retina, axial, refractive, and foveal development after anti-VEGF treatment including bevacizumab, ranibizumab, and aflibercept in infants with treatment requiring retinopathy of prematurity (ROP) in long term.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This retrospective chart review study included children with a history of any anti-VEGF monotherapy for ROP in Zone 1 or posterior Zone 2 who have reached at least 24 months of corrected age. The records of ophthalmologic examination including strabismus evaluation, visual acuity measurement, refractive and axial measurements, optical coherence tomography, and fundus fluorescein angiography examinations with RetCam III were reviewed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 36 eyes of 18 children met the inclusion criteria. The mean gestational age at birth was 27.8 \n                                    \n                                       \n                                    \n                                  2.13 (23\u201330) weeks, and ocular assessments were performed between 33 and 61.5 (mean: 42.58 \n                                    \n                                       \n                                    \n                                  8.6) months of corrected age. Treatment was with bevacizumab in 10 eyes, with ranibizumab in 14 eyes, and with aflibercept in 12 eyes. The mean spherical equivalent was \u22120.25 \n                                    \n                                       \n                                    \n                                  1.82; axial length was 20.81\n                                    \n                                       \n                                    \n                                  0.62 mm. There was no significant difference among three anti-VEGF groups regarding the abnormal vascular retinal development (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.183) or leakage (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.842) on fluorescein angiography.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>All the anti-VEGF agents provided similar adequate axial and refractive development as well as similar abnormal vascular development in the peripheral retina. The long-term impact of this abnormally vascularized peripheral retina is a curiosity issue. From this point of view, it is an important need to determine the follow-up period and method after the anti-VEGF treatment for ROP.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003590","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T20:00:08Z","timestamp":1660420808000},"page":"2194-2202","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["LONG-TERM EFFECTS OF ANTI-VEGF MONOTHERAPY FOR RETINOPATHY OF PREMATURITY ON THE RETINAL AND REFRACTIVE DEVELOPMENT OF EYE"],"prefix":"10.1097","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2315-434X","authenticated-orcid":false,"given":"Emine Alyama\u00e7","family":"Sukgen","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Gazi University Faculty of Medicine, Ankara, Turkey; and"},{"name":"Department of Ophthalmology, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice Tuba","family":"Atalay","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Gazi University Faculty of Medicine, Ankara, Turkey; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeng\u00fcl","family":"\u00d6zdek","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Gazi University Faculty of Medicine, Ankara, Turkey; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250607","first-page":"96","article-title":"Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an American Ophthalmological Society thesis)","volume":"108","author":"Hartnett","year":"2010","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1001\/archopht.1995.01100120068012","article-title":"Hypoxic regulation of vascular endothelial growth factor in retinal cells","volume":"113","author":"Aiello","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.iio.0000212142.15794.30","article-title":"Ranibizumab treatment of patients with ocular diseases","volume":"46","author":"Dugel","year":"2006","journal-title":"Int Ophthalmol Clin"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet (London, England)"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefe's Archive Clin Exp Ophthalmol"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"C1358","DOI":"10.1152\/ajpcell.2001.280.6.C1358","article-title":"Role of vascular endothelial growth factor in regulation of physiological angiogenesis","volume":"280","author":"Ferrara","year":"2001","journal-title":"Am J Physiol Cel Physiol"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","article-title":"Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury","volume":"171","author":"Nishijima","year":"2007","journal-title":"Am J Pathol"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000442498","article-title":"Changes in ocular growth after pediatric cataract surgery","volume":"57","author":"Lambert","year":"2016","journal-title":"Dev Ophthalmol"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1167\/iovs.04-1040","article-title":"Axial growth and changes in lenticular and corneal power during emmetropization in infants","volume":"46","author":"Mutti","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1755-3768.1971.tb05939.x","article-title":"The sagittal growth of the eye. IV. Ultrasonic measurement of the axial length of the eye from birth to puberty","volume":"49","author":"Larsen","year":"1971","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/bjo.80.10.918","article-title":"Reappraisal of the human ocular growth curve in fetal life, infancy, and early childhood","volume":"80","author":"Fledelius","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/archopht.1985.01050060045020","article-title":"Refractive development of the human eye","volume":"103","author":"Gordon","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jaapos.2011.12.157","article-title":"Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children","volume":"16","author":"Blair","year":"2012","journal-title":"J AAPOS"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings","volume":"125","author":"Lepore","year":"2018","journal-title":"Ophthalmology"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/IAE.0000000000001996","article-title":"Fluorescein angiographic evaluation of peripheral retinal vasculature after primary intravitreal ranibizumab for retinopathy of prematurity","volume":"39","author":"Harper","year":"2019","journal-title":"Retina"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ophtha.2011.01.028","article-title":"Structural grading of foveal hypoplasia using spectral-domain optical coherence tomography: a predictor of visual acuity?","volume":"118","author":"Thomas","year":"2011","journal-title":"Ophthalmology"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5935\/0004-2749.20140039","article-title":"Ocular biometry and central corneal thickness in children: a hospital-based study","volume":"77","author":"Gul","year":"2014","journal-title":"Arq Bras de Oftalmol"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/0042-6989(94)00262-K","article-title":"The equivalent refractive index of the crystalline lens in childhood","volume":"35","author":"Mutti","year":"1995","journal-title":"Vis Res"},{"key":"R23-20250607","first-page":"815","article-title":"Axial length development in children","volume":"12","author":"Bach","year":"2019","journal-title":"Int J Ophthalmol"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"42","author":"Gunay","year":"2017","journal-title":"Curr Eye Res"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1097\/IAE.0000000000002754","article-title":"Anatomical and functional results of intravitreal aflibercept monotherapy for type 1 retinopathy of prematurity: one-year outcomes","volume":"40","author":"Chen","year":"2020","journal-title":"Retina"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"806","DOI":"10.18240\/ijo.2020.05.17","article-title":"Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a meta-analysis","volume":"13","author":"Wang","year":"2020","journal-title":"Int J Ophthalmol"},{"key":"R27-20250607","first-page":"79","article-title":"Fluorescein angiography of retinal vascular involution after intravitreal injection of ranibizumab for retinopathy of prematurity","volume":"12","author":"Cheng","year":"2019","journal-title":"Int J Ophthalmol"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s10792-018-1040-x","article-title":"Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by periodic fluorescence angiography and optical coherence tomography","volume":"39","author":"Vural","year":"2019","journal-title":"Int Ophthalmol"},{"key":"R29-20250607","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.oret.2019.01.016","article-title":"Fluorescein angiography in retinopathy of prematurity: comparison of infants treated with bevacizumab to those with spontaneous regression","volume":"3","author":"Mansukhani","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"R30-20250607","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"R31-20250607","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1167\/iovs.14-16021","article-title":"Delay in retinal photoreceptor development in very preterm compared to term infants","volume":"56","author":"Vajzovic","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R32-20250607","doi-asserted-by":"crossref","first-page":"101018","DOI":"10.1016\/j.preteyeres.2021.101018","article-title":"Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF)","volume":"88","author":"Tsai","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"R33-20250607","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajo.2018.05.002","article-title":"Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment","volume":"192","author":"Lee","year":"2018","journal-title":"Am J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:02:41Z","timestamp":1749319361000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003590","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"2021-05-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}